KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Current Deferred Revenue (2018 - 2025)

Vir Biotechnology's Current Deferred Revenue history spans 8 years, with the latest figure at $10.1 million for Q2 2025.

  • For Q2 2025, Current Deferred Revenue fell 39.47% year-over-year to $10.1 million; the TTM value through Jun 2025 reached $10.1 million, down 39.47%, while the annual FY2024 figure was $12.6 million, 80.5% down from the prior year.
  • Current Deferred Revenue for Q2 2025 was $10.1 million at Vir Biotechnology, down from $11.9 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $262.9 million in Q1 2021 and bottomed at $10.1 million in Q2 2025.
  • The 5-year median for Current Deferred Revenue is $16.2 million (2023), against an average of $48.0 million.
  • The largest annual shift saw Current Deferred Revenue soared 5148.08% in 2021 before it tumbled 94.1% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $98.2 million in 2021, then crashed by 84.2% to $15.5 million in 2022, then surged by 317.95% to $64.9 million in 2023, then plummeted by 80.5% to $12.6 million in 2024, then fell by 20.07% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Current Deferred Revenue are $10.1 million (Q2 2025), $11.9 million (Q1 2025), and $12.6 million (Q4 2024).